Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HCRYP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
US20240245795A1 Antibody Conjugate 2
|
|||||
| Synonyms |
Antibody Conjugate 2
Click to Show/Hide
|
|||||
| Organization |
HYSLINK THERAPEUTICS
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7-8
|
|||||
| Antibody Name |
trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Deruxtecan
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.117 nM | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Chemiluminescence staining (Luminescent Cell Viability Assay) was carried out, and IC5owas calculated after reading the fluorescence data.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||